Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma

Annals of Oncology

Volumn 8, Issue 4, 1997, Pages 379-383

  Zinzani, P L ^a,b   Bendandi, M ^a   Magagnoli, M ^a   Gherlinzoni, F ^a   Merla, E ^a   Tura, S ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Fludarabine; Mitoxantrone; Non Hodgkin's lymphoma; Response rate

Indexed keywords

FLUDARABINE; MITOXANTRONE; PREDNISONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPENIA; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, LOW-GRADE; MALE; MIDDLE AGED; MITOXANTRONE; PREDNISONE; RECURRENCE; TREATMENT OUTCOME; VIDARABINE;

EID: 0030972725     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008228709612     Document Type: Article

References (39)

1. Paryani SB, Hoppe RT, Cox RS et al. Analysis of non-Hodgkin's lymphoma with nodular and favorable histologies, stage I and II. Cancer 1983; 52: 2300-7.
2. Gospodarowicz MK, Bush RS, Brown TC et al. Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret Hospital experience. Int J Radiat Oncol Phys 1984; 10: 489-97.
3. McLaughlin P, Fuller LM, Velasquez WS et al. Stage I II follicular lymphoma. Cancer 1986; 58: 1596-602.
4. Portlock CS, Fisher DS, Cadman E et al. High-dose chlorambucil in advanced, low-grade non-Hodgkin's lymphomas. Cancer Treat Rep 1987; 71: 1029-31.
5. Grossbard ML, Gribben JG, Freedman AS et al. Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood 1993; 81: 2263-71.
6. Press OW, Eary JF, Badger CC et al. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 1989; 7: 1027-35.
7. Redman JR, Cabanillas F, Velasquez WS et al. Phase II trial of fludarabine phosphate in lymphoma: An effective new agent in low-grade lymphoma. J Clin Oncol 1992; 109: 790-4.
8. Hochster HS, Kim K, Green MD et al. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: Results of an Eastern Cooperative Oncology Group study. J Clin Oncol 1992; 10: 28-32.
9. Zinzani PL, Lauria F, Rondelli D et al. Fludarabine: An active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. Ann Oncol 1993; 4: 575-8.
10. Hiddeman W, Unterhalt M, Pott C et al. Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: A phase II study of the German low-grade non-Hodgkin's lymphoma study group. Semin Oncol 1993; 20: 28-31.
11. Kay AC, Saven A, Carrera CJ et al. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol 1992; 10: 371-7.
12. Hoffman M, Tallman MS, Hakimian D et al. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 788-92.
13. Pigaditou A, Rohatiner AZS, Whelan JS et al. Fludarabine in low-grade lymphoma. Semin Oncol 1993; 20: 24-7.
14. Dumontet C, Bastion Y, Bazin M et al. Fludarabine treatment in low-grade non-Hodgkin's Lymphoma: Results of the Lyon-Sud experience. Fifth International Conference on Malignant Lymphoma, Lugano, Switzerland. 1993 (Abstr 108).
15. McLaughlin P, Hagemeister FB, Swan F et al. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol 1994; 12: 575-9.
16. Pott C, Unterhalt M, Sandford D et al. Fludarabine as single agent and in combination with mitoxantrone and dexamethasone in relapsed and refractory low-grade non-Hodgkin's lymphoma. Ann Haematol 1994; 68 (Suppl 1): A3.
17. Zinzani PL, Bendandi M, Tura S. FMP regimen (fludarabine, mitoxantrone. prednisone) as therapy in recurrent low-grade non-Hodgkin's lymphoma. Eur J Haematol 1995; 55: 262-6.
18. McLaughlin P, Hagemeister FB, Ramaguera JE et al. Fludarabine, mitoxantrone, and dexamethasone: An effective new regimen for indolent lymphoma. J Clin Oncol 1996; 14: 1262-8.
19. Zinzani PL, Bendandi M, Gherlinzoni F et al. FLU-ID (fludarabine and idarubicin) regimen as salvage therapy in pretreated low-grade non-Hodgkin's lymphoma. Haematologica 1996; 81: 168-71.
20. Hochster H, Oken M, Bennett J et al. Efficacy of cyclophosphamide (CYC) and fludarabine (FAMP) as first line therapy of low-grade non-Hodgkin's lymphoma (NHL) - ECOG 1491. Blood 1994; 84 (Suppl 1): 383a.
21. Stansfeld AG, Diebold J, Kapanci Y et al. Updated Kiel classification for lymphomas. Lancet 1988; 1: 292-3.
22. Carbone PP, Kaplan HS, Musshoff K et al. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971; 31: 1860-1.
23. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
24. Oken M, Creech R, Tormey D. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
25. Cox DR. Regression models and life tables. J R Stat Soc Ser B 1972; 34: 187-202.
26. Shipp M, Harrington D, Anderson J et al. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-94.
27. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphoma. N Engl J Med 1984; 311: 1471-5.
28. Young RC, Longo DL, Glatstein E et al. The treatment of indolent lymphomas: Watchful waiting v. aggressive combined modality treatment. Semin Hematol 1988; 25: 11-6.
29. Freedman A, Ritz J, Neuberg D et al. Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma. Blood 1991; 77: 2524-9.
30. Colombat P, Binet C, Linassier C et al. High-dose chemotherapy with autologous marrow trasplantation in follicular lymphomas. Leuk Lymphoma 1992; 7: 3-6.
31. Freedman AS, Gribben JG. Neuberg D et al. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996; 88: 2780-6.
32. Dana BW, Dahlberg S, Nathwani BN et al. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 1993; 11: 644-51.
33. Zinzani PL, Mazza P, Gherlinzoni F et al. CEOP regimen in the treatment of advanced low-grade non-Hodgkin's lymphomas: Preliminary report. Tumori 1990; 76: 533-6.
34. Gams RA, Bryan S, Dukart G et al. Mitoxantrone in malignant lymphoma. Invest New Drugs 1985; 3: 219-22.
35. Silvert RT, Case DC, Wheeler RH et al. Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease. J Clin Oncol 1991; 9: 754-61.
36. Robertson LE. Chubb S, Mayn RE et al. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-β-D-arabinosyl-2-fluoroadenine. Blood 1993; 81: 143-50.
37. Zinzani PL, Tosi P, Visani G et al. Apoptosis induction with three nucleoside analogs of freshly isolated B-chronic lymphocytic leukemia cells. Am J Hematol 1994; 47: 301-6.
38. Solal-Céligny P, Brice P, Brousse N et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: A multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1996; 14: 514-9.
39. McLaughlin P, Cabanillas F, Younes A et al. Stage IV low grade lymphoma (LGL): Randomized trial of two innovative regimens, with monitoring of bel-2 by PCR. Ann Oncol 1996; 7 (Suppl 3): 34 (Abstr 109).